Cefazolin is Generally Preferred Over Ceftriaxone (Rocephin) for Treating Cellulitis in a 76-Year-Old Man
For uncomplicated cellulitis in this patient, cefazolin is the better choice as it provides equivalent efficacy to ceftriaxone while offering narrower-spectrum coverage, reducing selective pressure for resistant organisms and C. difficile infection. Both agents are FDA-approved and guideline-supported for skin and soft tissue infections, but cefazolin should be prioritized when methicillin-susceptible Staphylococcus aureus (MSSA) and streptococci are the suspected pathogens 1, 2.
Evidence Supporting Cefazolin
The 2014 IDSA guidelines explicitly list cefazolin (1 g every 8 hours IV) as first-line therapy for staphylococcal skin infections, while ceftriaxone is reserved for specific scenarios like polymicrobial necrotizing infections or water-borne pathogens (Aeromonas, Vibrio) 3. This guideline framework prioritizes narrow-spectrum agents when appropriate.
Multiple high-quality studies demonstrate equivalence:
- A 2002 randomized double-blind trial showed cefazolin plus probenecid achieved 86% clinical cure versus 96% for ceftriaxone (p=0.11), with maintained cure at 1-month follow-up (96% vs 91%, p=0.55) 4
- A 1996 randomized double-blind study of 194 patients found no statistical difference in treatment outcomes between cefazolin and ceftriaxone for outpatient cellulitis management 5
- A 2013 retrospective study of 122 MSSA infections showed similar favorable outcomes (67.9% vs 79.8%, p=0.17) and adverse events between cefazolin and ceftriaxone 6
Clinical Decision Algorithm
Use cefazolin when:
- Non-purulent cellulitis without systemic toxicity
- No risk factors for MRSA (no recent hospitalization, no injection drug use, no prior MRSA)
- Suspected streptococcal or MSSA infection
- Patient can receive IV therapy (inpatient or outpatient parenteral antimicrobial therapy)
Consider ceftriaxone instead when:
- Polymicrobial infection suspected (perianal, diabetic foot with multiple organisms)
- Water exposure with concern for Vibrio or Aeromonas 3
- Once-daily dosing is critical and probenecid cannot be added to cefazolin
- Patient has severe penicillin allergy requiring alternative (though neither would be used in this case)
Dosing Considerations for a 76-Year-Old
Standard cefazolin dosing: 1-2 g every 8 hours IV 3. For elderly patients, renal function assessment is critical as cefazolin is renally excreted 1. Dose adjustment may be needed if creatinine clearance is reduced.
Ceftriaxone dosing: 1-2 g every 24 hours IV 2. While convenient for once-daily dosing, this is not sufficient justification to use broader-spectrum coverage.
Important caveat: If the patient weighs ≥120 kg, recent 2025 data suggests cefazolin 3 g dosing may improve outcomes, with a 63.7% probability of better outcomes compared to standard dosing 7.
Antimicrobial Stewardship Perspective
Cefazolin is the superior choice from a stewardship standpoint. The 2026 systematic review emphasizes that probenecid-boosted cefazolin offers a narrower-spectrum alternative to ceftriaxone, reducing dependence on third-generation cephalosporins in ambulatory settings 8. This is increasingly important given rising antimicrobial resistance.
The 2018 WSES guidelines note that for typical cellulitis caused by streptococci and staphylococci, beta-lactams effective against Gram-positive organisms are first-line, with broader agents reserved for specific clinical scenarios 9.
Common Pitfalls to Avoid
Don't reflexively choose ceftriaxone for convenience alone - Once-daily dosing can be achieved with cefazolin plus probenecid if needed 4, 8
Don't use ceftriaxone empirically when MRSA is suspected - Neither agent covers MRSA; vancomycin should be added if MRSA is a concern 3, 9
Don't forget to assess renal function in elderly patients - Both drugs require dose adjustment in renal impairment, but cefazolin particularly so 1
Don't continue empiric therapy beyond 24-48 hours without reassessment - If no improvement, consider MRSA coverage, abscess requiring drainage, or alternative diagnosis 3
Safety Profile
Both agents are generally well-tolerated. Cefazolin may cause slightly more gastrointestinal side effects when combined with probenecid (nausea more common, p=0.048) 4. Neither significantly increases C. difficile risk in short-term use for cellulitis, though narrower spectrum theoretically favors cefazolin.
The bottom line: Cefazolin 1-2 g IV every 8 hours is the preferred agent for this 76-year-old man with cellulitis, assuming MSSA/streptococcal etiology and adequate renal function. Reserve ceftriaxone for specific indications where its broader spectrum or once-daily dosing provides clear clinical advantage that outweighs stewardship concerns.